Clarification regarding Intervacc’s vaccine Strangvac

Stockholm, December 17, 2021 - Due to the large and volatile trading in the company's share based on speculations on social media, Intervacc wants to clarify that Strangvac is centrally approved by EMA for sales throughout the EU and that sales will start during the first quarter of 2022.

Strangvac is centrally approved for sale throughout the EU, including Sweden, for vaccination of horses against the contagious bacterial disease strangles. Strangvac was unanimously approved by all Member States after an extensive evaluation process lasting 15 months. This means that the vaccine is safe, has a well-documented protective effect and an approved manufacturing process. We are proud to be one of the few pharmaceutical companies to have had a veterinary vaccine approved through the EMA's central approval process, and by the Veterinary Medicines Directorate (VMD) for the United Kingdom.

The approval is based on robust studies that show that even two doses of Strangvac provide significant levels of protection, which forms the basis for the approval of EMA and VMD. In addition, published studies (Robinson et al., 2020) show that a third dose (booster) increased protection against strangles up to 94%. Neither EMA's nor VMD's approvals are subject to the need for further studies.

We have received a great deal of interest in Strangvac from both veterinarians and horse owners and we are convinced that Strangvac will be widely used based on the desire to vaccinate horses against such a devastating and contagious disease.

For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on December 17, 2021, 17.15 CET.

This Press Release has been prepared in a Swedish original version published at 08.30 CET.

About Intervacc
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10

Date Created

2021-12-17